AACE MENA 2025-GLP1 use in T1DM

Video Transcription

Video Summary

The speaker discussed the role of GLP-1 receptor agonists (GLP-1 RAs) in type 1 diabetes (T1D), highlighting increasing obesity and insulin resistance among T1D patients. GLP-1 RAs, while not currently guideline-approved for T1D, are increasingly prescribed due to their potential benefits beyond glycemic control, including cardiovascular, liver, and kidney protection. They work by glucose-dependent inhibition of glucagon, a mechanism considered favorable compared to amylin, the only approved adjunct therapy. Clinical trials with liraglutide, semaglutide, and tirzepatide showed modest yet significant A1c reductions, weight loss, and sometimes reduced insulin requirements, especially in overweight/obese adults with some residual insulin secretion. Although there is a risk of ketoacidosis, it was mostly associated with precipitating factors. The speaker emphasized the need for more data on youth, normal-weight patients, and long-term use. Overall, GLP-1 RAs show promise as adjunct therapy in T1D but require careful patient selection and further research before guideline incorporation.

Keywords

GLP-1 receptor agonists

type 1 diabetes

insulin resistance

glycemic control

cardiovascular protection

adjunct therapy